Systematic treatment

Adjuvant systemic therapy has improved recurrence-free and overall survival after breast cancer. Intensive research is underway to achieve a better understanding of the different oncogenesis cascades and their flaws, and to identify predictive factors in order to more accurately define the patient group that could benefit from a particular treatment. The choice is complex and will depend on the stage and, above all, on the biological characteristics of the tumour involved. In some cases, it is difficult to assess the potential benefit of chemotherapy.

The best, most effective and least toxic treatment must be found for each patient.

Through multidisciplinary conferences (tumour boards), medical oncologists, breast surgeons, radiation oncologists and pathologists evaluate together the best treatment approach for each individual patient.

Hormone therapy
Adjuvant chemotherapy
Neo-adjuvant systemic therapy
Anti-HER2 immunotherapy

Promising treatments

Considerable progress is being made and therapeutic approaches are being adapted accordingly.

Thanks to the Breast Centre’s collaboration with groups at the forefront of research, its patients will have access to all kinds of medication approved for the «breast cancer» indication as soon as the marketing authorisation is granted or, in some cases, even within the framework of studies that are still being monitored by the Federal and Cantonal Health Authorities.